Skip to main content
Caplight Logo









Zhimeng Biopharma

Zhimeng Biopharma

Private
ShanghaiHealthcare & Life Scienceshttp://core-biopharma.com/

Last Round

Series B

Nov 8, 2021

Total Funding Raised

$98M

Company Overview

Zhimeng Biopharma is a biopharmaceutical company that develops innovative small-molecule therapeutics for the treatment of chronic hepatitis B and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall-molecule therapeuticschronic hepatitis BCHBCNS disordersamyotrophic lateral sclerosisALSclinical-stage biotechcapsid assembly modulatorspotassium channel openerbiopharma licensingdrug pipelineclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zhimeng Biopharma Comparables

Compare Zhimeng Biopharma with similar companies based on industry and business-model similarity.

Zhimeng Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuShen Therapeutics
78%
Shanghai Hepu Pharmaceutical Co., Ltd.
74%
Brii Biosciences
74%

Zhimeng Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2021
Series ANov 6, 2020
Pre SeedNov 11, 2019

Zhimeng Biopharma Investors

Notable investors and investment history

Zhimeng Biopharma investors
InvestorRounds
Photon FundSeries A
SDIC Unity CapitalSeries A
中南创投基金Series A
Shenzhen Dachen Caizhi Venture Capital ManagementSeries B
Trinity Innovation FundSeries A
Advantech CapitalSeries B
Lake CapitalSeries A, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 5, 2026

    Monthly visitors increased 112% MoM.

Zhimeng Biopharma Filings

Explore SEC and related filing metadata, where available.

Zhimeng Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Zhimeng Biopharma's valuation, stock price, and market status.

Is Zhimeng Biopharma a public or private company?

Zhimeng Biopharma is a private company.

What is the current stock price of Zhimeng Biopharma?

Zhimeng Biopharma is a private company with no public stock price. No recent secondary market data is available.

How much is Zhimeng Biopharma worth (valuation)?

Valuation information for Zhimeng Biopharma is not publicly available.

Can I buy Zhimeng Biopharma stock?

Zhimeng Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Zhimeng Biopharma's last funding round?

Zhimeng Biopharma's most recent funding round was Series B on November 8, 2021.

Who are the main investors in Zhimeng Biopharma?

Key investors in Zhimeng Biopharma include Trinity Innovation Fund, Lake Capital.

Will Zhimeng Biopharma IPO soon?

No public IPO plans have been announced for Zhimeng Biopharma.

How can I track Zhimeng Biopharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Zhimeng Biopharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range1
Year Founded2017
Last FundingNov 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?